J

Joincare Pharmaceutical Group Industry Co Ltd
SSE:600380

Watchlist Manager
Joincare Pharmaceutical Group Industry Co Ltd
SSE:600380
Watchlist
Price: 11.42 CNY 0.26% Market Closed
Market Cap: 21.4B CNY
Have any thoughts about
Joincare Pharmaceutical Group Industry Co Ltd?
Write Note

Joincare Pharmaceutical Group Industry Co Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Joincare Pharmaceutical Group Industry Co Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
J
Joincare Pharmaceutical Group Industry Co Ltd
SSE:600380
Total Equity
ÂĄ14.3B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
13%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Equity
ÂĄ25.8B
CAGR 3-Years
13%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Equity
ÂĄ13.7B
CAGR 3-Years
14%
CAGR 5-Years
17%
CAGR 10-Years
18%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Equity
ÂĄ42.6B
CAGR 3-Years
8%
CAGR 5-Years
13%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Equity
ÂĄ39.4B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
14%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Equity
ÂĄ151.9m
CAGR 3-Years
-30%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Joincare Pharmaceutical Group Industry Co Ltd
Glance View

Market Cap
21.4B CNY
Industry
Pharmaceuticals

Joincare Pharmaceutical Group Industry Co. Ltd., a noteworthy player in China's bustling pharmaceutical landscape, emerged as a beacon of innovation and resilience. With its roots stretching back to the mid-1990s, the company has consistently carved out a substantial niche in both the generic and proprietary drug markets. Its ability to synergistically blend cutting-edge research with cost-efficient production has been instrumental in ensuring its position as a formidable competitor. Joincare harnesses a robust pipeline of drugs targeting prevalent chronic diseases, complemented by its investment in high-growth biopharmaceuticals. From research and development to manufacturing and distribution, Joincare manages an integrated pharmaceutical supply chain that not only propels its profitability but also reinforces its mission to enhance public health. The company thrives on a diverse revenue model by leveraging both its proprietary products and a broad array of generic pharmaceuticals. It capitalizes on sustained demand for its products across domestic and international markets, ensuring a steady stream of income. By focusing on quality and affordability, Joincare has successfully navigated the complex regulatory landscape, earning certifications that open doors to global markets. This strategic emphasis on rigorous compliance not only mitigates risks but also builds trust with healthcare professionals and end-users alike. Through these efforts, Joincare continues to fortify its market position, all while contributing to the ever-evolving pharmaceutical industry with a pioneering spirit and an unwavering commitment to improving healthcare accessibility.

Intrinsic Value
18.96 CNY
Undervaluation 40%
Intrinsic Value
Price
J

See Also

What is Joincare Pharmaceutical Group Industry Co Ltd's Total Equity?
Total Equity
14.3B CNY

Based on the financial report for Sep 30, 2024, Joincare Pharmaceutical Group Industry Co Ltd's Total Equity amounts to 14.3B CNY.

What is Joincare Pharmaceutical Group Industry Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
13%

Over the last year, the Total Equity growth was 7%. The average annual Total Equity growth rates for Joincare Pharmaceutical Group Industry Co Ltd have been 8% over the past three years , 7% over the past five years , and 13% over the past ten years .

Back to Top